KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash from Operations: 2019-2024

Historic Cash from Operations for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to -$108.6 million.

  • AbCellera Biologics' Cash from Operations fell 82.10% to -$52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$104.6 million, marking a year-over-year increase of 12.99%. This contributed to the annual value of -$108.6 million for FY2024, which is 147.41% down from last year.
  • Latest data reveals that AbCellera Biologics reported Cash from Operations of -$108.6 million as of FY2024, which was down 147.41% from -$43.9 million recorded in FY2023.
  • In the past 5 years, AbCellera Biologics' Cash from Operations registered a high of $277.4 million during FY2022, and its lowest value of -$108.6 million during FY2024.
  • In the last 3 years, AbCellera Biologics' Cash from Operations had a median value of -$43.9 million in 2023 and averaged $41.6 million.
  • Per our database at Business Quant, AbCellera Biologics' Cash from Operations soared by 977.94% in 2021 and then tumbled by 147.41% in 2024.
  • AbCellera Biologics' Cash from Operations (Yearly) stood at $22.7 million in 2020, then spiked by 977.94% to $244.6 million in 2021, then increased by 13.40% to $277.4 million in 2022, then tumbled by 115.82% to -$43.9 million in 2023, then crashed by 147.41% to -$108.6 million in 2024.